Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study

Michel Ducreux; Andrew X. Zhu; Shukui Qin; Masafumi Ikeda; Tae‐You Kim; Ho Yeong Lim; Masatoshi Kudo; В. В. Бредер; Philippe Merle; Ahmed O. Kaseb; Daneng Li; Wendy Verret; Zhen Xu; Sairy Hernandez; Juan Liu; Hui Shao; Huang Chen; Ann-LII Cheng; Richard S. Finn; Peter R. Galle

doi:10.1016/s0168-8278(20)30759-5

Related publications

Article2023

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Masatoshi Kudo, Richard S. Finn, Ann‐Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel

Article2022

Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo

Article2021

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn

Article2020

O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150

D. Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Hui Shao, S. Mulla, Beiying Ding, Masatoshi Kudo

Article2021

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Andrew X. Zhu, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Juan Liu, Chen Huang, Ho Yeong Lim, Ann‐Lii Cheng, Michel Ducreux